Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

How Will the Trump Presidency Affect Pharmaceutical Marketing?

XTALKS VITALS NEWS

Trump

Among those in the industry who could be most affected are pharmaceutical marketers, whose job centers around direct-to-consumer (DTC) advertising for prescription drugs.

Share this!

November 30, 2016 | by Sarah Hand, M.Sc.

Donald Trump’s election win could have significant effects on the pharmaceutical industry, but whether these changes will be good or bad has yet to be seen. Among those in the industry who could be most affected are pharmaceutical marketers, whose job centers around direct-to-consumer (DTC) advertising for prescription drugs.

Recently, an article published on FiercePharma outlined some current pharmaceutical industry perspectives on what Trump’s presidency could have in store for drugmakers. The industry is currently benefitting from a consistent flow of US Food and Drug Administration (FDA) approvals, keeping pharmaceutical marketers busy with advertising the drugs to consumers.

“While pharmaceutical companies may have a wait-and-see approach in some areas, such as pending healthcare legislation, I just don’t see ad spending slowing,” Wendy Blackburn, executive VP at pharmaceutical marketing agency, Intouch Solutions, told FiercePharma. “It’s likely safe to say the general consensus is that Trump’s election is a positive for this industry.”



As long as the FDA continues to approve drugs at the rate its going, industry insiders like John Kamp, executive director at the Coalition for Healthcare Communication, believe that pharmaceutical ad spending should stay the same. However, Trump has announced that he plans to reform the FDA by cutting red tape and expediting the approval of potentially life-saving drugs.

“The only thing that would negatively affect spending is if Trump had Medicare negotiate directly on lowering drug prices,” Bob Ehrlich, chairman-CEO of DTC Perspectives, told FiercePharma. While Ehrlich admitted that this was a possibility, he believes that Trump may lean toward the pharmaceutical industry’s side of the drug pricing debate.

Historically, the pharmaceutical industry has been less-reactive to changes in government compared to other sectors which rely on consumer marketing. This wait-and-see approach is leading many in the industry to hold their speculations until the president-elect takes office next year.


Keywords: Pharmaceutical Marketing, Pharmaceutical Industry, DTC Advertising


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.